Click to edit Master title style Starting a Cardio-Oncology Program Our experience in the Community setting Kibar Yared, MD FRCPC Director, Cardiac Imaging Medical Director, Cardio-Oncology Program Scarborough Health Network Clinical Adjunct Professor of Medicine University of Toronto @kibaryared
15
Embed
Click to edit Master title style - Cardiac Oncologycardiaconcology.ca/wp-content/uploads/23.-Kibar... · mortality from noncancer causes, predominantly cardiovascular disease (CVD).
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
ClicktoeditMastertitlestyle
Starting a Cardio-Oncology Program Our experience in the Community settingKibar Yared, MD FRCPC Director, Cardiac Imaging Medical Director, Cardio-Oncology Program Scarborough Health Network Clinical Adjunct Professor of Medicine University of Toronto
@kibaryared
ClicktoeditMastertitlestyle
@SHNcares
• Who came up with this idea and why? • How it started • Challenges • Success stories • Where are we headed?
Outline
@SHNcares
ClicktoeditMastertitlestyle
@SHNcares
• American Society of Echocardiography Scientific Sessions 2015 – Particularly compelling presentation by Dr. Juan Carlos Plana
• Audited our current practices and found: – All cardiac investigations ordered and followed-up by
Oncology
– If abnormal then referral sent to first-available Cardiologist – Large discrepancies in
• Time for patient to be assessed • Management • Follow-up
Who came up with this and why?
ClicktoeditMastertitlestyle
@SHNcares
• No official Cardio-Oncology Clinic – But there was established Heart Function Clinic, staffed with clerk
and nurses • Met with point person in Oncology, Dr. Orit Freedman, with same
motivation – Established what type of patient should be seen in Cardio-Oncology – Agreed that we would “take over” cardiac investigations of patients
at risk of cardiotoxicity • Included all patients on Anthracycline +/- Trastuzumab • Patients with established heart disease about to undergo
chemotherapy • Patients currently undergoing chemotherapy with cardiac
complaints or previous abnormal cardiac investigations
How it started
ClicktoeditMastertitlestyle
@SHNcares
• Met again with all Oncologists to discuss – Referral pattern – Logistics of how we would deal with referral
• Triage • Timing of investigations and consultation
– Communication (!)
How it started
ClicktoeditMastertitlestyle
@SHNcares
ClicktoeditMastertitlestyle
@SHNcares
8474
74
(Rev
.03/
17) P
age
1 of
1847474
OUTPATIENT CARDIO−ONCOLOGYHISTORY
Distribution: Chart Copy
Chemotherapy #1 ________________________________ Date ___________________________________________# of Tx’s received _________________ Last Tx date_________________ Next Planned Tx date__________________Chemotherapy #2 ________________________________Date ____________________________________________# of Tx’s received _________________ Last Tx date _________________ Next Planned Tx date __________________Chemotherapy #3 ________________________________Date ____________________________________________# of Tx’s received _________________ Last Tx date _________________ Next Planned Tx date __________________Chemotherapy #4 ________________________________Date ____________________________________________# of Tx’s received _________________ Last Tx date _________________ Next Planned Tx date __________________
Previous childhood/adolescent malignancyDiagnosis ______________________ Date _________________ Treatment ___________________
Previous Cardio Toxicity: ❏ Yes ❏ No Date:__________________________Priamary Cardiologist ______________________
Oncologist: HER2 #of Tx:Date: Radiation Date:Date Cancer Diagnosis: Surgical Date:
8474
74
(Rev
.03/
17) P
age
1 of
1847474
OUTPATIENT CARDIO−ONCOLOGYHISTORY
Distribution: Chart Copy
Chemotherapy #1 ________________________________ Date ___________________________________________# of Tx’s received _________________ Last Tx date_________________ Next Planned Tx date__________________Chemotherapy #2 ________________________________Date ____________________________________________# of Tx’s received _________________ Last Tx date _________________ Next Planned Tx date __________________Chemotherapy #3 ________________________________Date ____________________________________________# of Tx’s received _________________ Last Tx date _________________ Next Planned Tx date __________________Chemotherapy #4 ________________________________Date ____________________________________________# of Tx’s received _________________ Last Tx date _________________ Next Planned Tx date __________________
Previous childhood/adolescent malignancyDiagnosis ______________________ Date _________________ Treatment ___________________
Previous Cardio Toxicity: ❏ Yes ❏ No Date:__________________________Priamary Cardiologist ______________________
Oncologist: HER2 #of Tx:Date: Radiation Date:Date Cancer Diagnosis: Surgical Date:
8474
74
(Rev
.03/
17) P
age
1 of
1847474
OUTPATIENT CARDIO−ONCOLOGYHISTORY
Distribution: Chart Copy
Chemotherapy #1 ________________________________ Date ___________________________________________# of Tx’s received _________________ Last Tx date_________________ Next Planned Tx date__________________Chemotherapy #2 ________________________________Date ____________________________________________# of Tx’s received _________________ Last Tx date _________________ Next Planned Tx date __________________Chemotherapy #3 ________________________________Date ____________________________________________# of Tx’s received _________________ Last Tx date _________________ Next Planned Tx date __________________Chemotherapy #4 ________________________________Date ____________________________________________# of Tx’s received _________________ Last Tx date _________________ Next Planned Tx date __________________
Previous childhood/adolescent malignancyDiagnosis ______________________ Date _________________ Treatment ___________________
Previous Cardio Toxicity: ❏ Yes ❏ No Date:__________________________Priamary Cardiologist ______________________
❏ Yes ❏ No ❏ Productive ❏ Non Productive Onset❏ Yes ❏ No❏ Yes ❏ No
Regular Exercise
DiagnosticsEcho EF ______________________ Date_________________ MUGA EF_________________ Date___________Cardiac MRI EF_________________ Date _________________
Philip A. Ades, MDCatherine M. Alfano, PhDBarry A. Franklin, PhD,
FAHALee W. Jones, PhDAndre La Gerche, MBBS,
PhDJennifer A. Ligibel, MDGabriel Lopez, MDKushal Madan, PhD, FAHAKevin C. Oeffinger, MDJeannine Salamone, BAJessica M. Scott, PhDRay W. Squires, PhD, FAHARandal J. Thomas, MD,
MS, FAHADiane J. Treat-Jacobson,
PhD, RN, FAHAJanet S. Wright, MDOn behalf of the Ameri-
can Heart Association Exercise, Cardiac Reha-bilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease
Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and SurvivorsA Scientific Statement From the American Heart Association Endorsed by the American Cancer Society
Circulation
https://www.ahajournals.org/journal/circ
ABSTRACT: Cardiovascular disease is a competing cause of death in patients with cancer with early-stage disease. This elevated cardiovascular disease risk is thought to derive from both the direct effects of cancer therapies and the accumulation of risk factors such as hypertension, weight gain, cigarette smoking, and loss of cardiorespiratory fitness. Effective and viable strategies are needed to mitigate cardiovascular disease risk in this population; a multimodal model such as cardiac rehabilitation may be a potential solution. This statement from the American Heart Association provides an overview of the existing knowledge and rationale for the use of cardiac rehabilitation to provide structured exercise and ancillary services to cancer patients and survivors. This document introduces the concept of cardio-oncology rehabilitation, which includes identification of patients with cancer at high risk for cardiac dysfunction and a description of the cardiac rehabilitation infrastructure needed to address the unique exposures and complications related to cancer care. In this statement, we also discuss the need for future research to fully implement a multimodal model of cardiac rehabilitation for patients with cancer and to determine whether reimbursement of these services is clinically warranted.
Advances in early detection and treatment have significantly improved the 5-year disease-specific survival rates for the 10 most common malignan-cies.1 As a result, there are >16.7 million cancer survivors in the United
States today.1–4 Many of these individuals are at increased risk of morbidity and mortality from noncancer causes, predominantly cardiovascular disease (CVD). Specifically, cancer survivors living at least 5 years beyond diagnosis have a 1.3- to 3.6-fold increased risk of cardiovascular-specific mortality and a 1.7- to 18.5-fold increased incidence of CVD risk factors such as hypertension, diabetes mellitus, and dyslipidemia compared with age-matched counterparts with no cancer his-tory.5,6 The elevated risk of CVD in cancer survivors is likely the result of normal age-related pathologies coupled with the direct (eg, radiation, chemotherapy, tar-geted therapy) and indirect (eg, deconditioning, weight gain)7 effects of cancer therapy that extend across multiple systems (ie, whole-organism cardiovascular toxicity).8 CVD is likely to become even more pervasive in the oncology setting as a result of continued improvements in cancer-specific mortality in conjunction with the rapidly aging population.9
Effective and viable strategies are needed to mitigate CVD risk in patients with cancer. The use of a delivery model similar to that used in cardiac rehabilitation
Key Words: AHA Scientific Statements ◼ cancer ◼ cardiac rehabilitation ◼ cardiovascular diseases
Philip A. Ades, MDCatherine M. Alfano, PhDBarry A. Franklin, PhD,
FAHALee W. Jones, PhDAndre La Gerche, MBBS,
PhDJennifer A. Ligibel, MDGabriel Lopez, MDKushal Madan, PhD, FAHAKevin C. Oeffinger, MDJeannine Salamone, BAJessica M. Scott, PhDRay W. Squires, PhD, FAHARandal J. Thomas, MD,
MS, FAHADiane J. Treat-Jacobson,
PhD, RN, FAHAJanet S. Wright, MDOn behalf of the Ameri-
can Heart Association Exercise, Cardiac Reha-bilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease
Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and SurvivorsA Scientific Statement From the American Heart Association Endorsed by the American Cancer Society
Circulation
https://www.ahajournals.org/journal/circ
ABSTRACT: Cardiovascular disease is a competing cause of death in patients with cancer with early-stage disease. This elevated cardiovascular disease risk is thought to derive from both the direct effects of cancer therapies and the accumulation of risk factors such as hypertension, weight gain, cigarette smoking, and loss of cardiorespiratory fitness. Effective and viable strategies are needed to mitigate cardiovascular disease risk in this population; a multimodal model such as cardiac rehabilitation may be a potential solution. This statement from the American Heart Association provides an overview of the existing knowledge and rationale for the use of cardiac rehabilitation to provide structured exercise and ancillary services to cancer patients and survivors. This document introduces the concept of cardio-oncology rehabilitation, which includes identification of patients with cancer at high risk for cardiac dysfunction and a description of the cardiac rehabilitation infrastructure needed to address the unique exposures and complications related to cancer care. In this statement, we also discuss the need for future research to fully implement a multimodal model of cardiac rehabilitation for patients with cancer and to determine whether reimbursement of these services is clinically warranted.
Advances in early detection and treatment have significantly improved the 5-year disease-specific survival rates for the 10 most common malignan-cies.1 As a result, there are >16.7 million cancer survivors in the United
States today.1–4 Many of these individuals are at increased risk of morbidity and mortality from noncancer causes, predominantly cardiovascular disease (CVD). Specifically, cancer survivors living at least 5 years beyond diagnosis have a 1.3- to 3.6-fold increased risk of cardiovascular-specific mortality and a 1.7- to 18.5-fold increased incidence of CVD risk factors such as hypertension, diabetes mellitus, and dyslipidemia compared with age-matched counterparts with no cancer his-tory.5,6 The elevated risk of CVD in cancer survivors is likely the result of normal age-related pathologies coupled with the direct (eg, radiation, chemotherapy, tar-geted therapy) and indirect (eg, deconditioning, weight gain)7 effects of cancer therapy that extend across multiple systems (ie, whole-organism cardiovascular toxicity).8 CVD is likely to become even more pervasive in the oncology setting as a result of continued improvements in cancer-specific mortality in conjunction with the rapidly aging population.9
Effective and viable strategies are needed to mitigate CVD risk in patients with cancer. The use of a delivery model similar to that used in cardiac rehabilitation
Key Words: AHA Scientific Statements ◼ cancer ◼ cardiac rehabilitation ◼ cardiovascular diseases
Dow
nloaded from http://ahajournals.org by on A
pril 18, 2019
ClicktoeditMastertitlestyle
@SHNcares
• Further participation in clinical trials – Statins for the Primary Prevention of Heart
Failure in Patients Receiving Anthracycline Pilot Study (SPARE-HF)
– Characterizing Heart And Mind health Post-chemotherapy In wOmeN with Breast Cancer (CHAMPION)
• Expansion across sites and regionally.
Where are we headed?
ClicktoeditMastertitlestyle
@SHNcares
Telemedicine
Where are we headed?
PatientAlternative access to care, reduced
travel costs
CliniciansImproved patient care and family/patient